Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1010 influenza vaccine in healthy adults
NCT05606965Phase 2Completed
- Sponsor
- Moderna Inc
- Start
- Nov 2022
- Primary completion
- Nov 2025
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of mRNA-1010 in influenza, sponsored by Moderna Inc. Started Nov 2022; status: completed.
02
Drugs
mRNA-1010
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05606965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05606965.